cITGs

:   ITGs closest to integration sites

dITGs

:   ITGs directly disrupted by HPV integration

EST

:   expressed sequence tag

GO

:   gene ontology

HBV

:   hepatitis B virus

HPV

:   human papillomavirus

ITG

:   integration‐targeted gene

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

RTG

:   recurrently targeted host genes

TPM

:   transcripts per million

HR‐HPV

:   high‐risk types of HPV

STR

:   short tandem repeats

**Brief description**: Genes targeted by human papillomavirus (HPV) integration (ITGs) are concentrated in transcriptionally active, gene‐dense regions and enriched in cancer‐related functional terms and pathways. Expression of *MYC* was decreased by "knocking out" the integrated HPV fragment in HeLa cell lines. *MPPED2*, one of the ITGs, has, for the first time, been identified as being involved in cervical carcinogenesis. This study highlights aberrant functioning of ITGs as a novel phenomenon of potential importance in HPV‐related cancers.

Cervical cancer is responsible for 10--15% of female cancer deaths worldwide.[1](#ijc29872-bib-0001){ref-type="ref"} Persistent human papillomavirus (HPV) infection, especially with the high‐risk types of HPV (HR‐HPV) 16 and/or 18, which account for about 70% of cervical cancers, is the predominant cause of cervical cancers.[2](#ijc29872-bib-0002){ref-type="ref"}, [3](#ijc29872-bib-0003){ref-type="ref"}, [4](#ijc29872-bib-0004){ref-type="ref"}, [5](#ijc29872-bib-0005){ref-type="ref"}, [6](#ijc29872-bib-0006){ref-type="ref"} HPV usually infect basal cells, and the viral genome is maintained as an episome in precancerous lesions. In most cases, HR‐HPV infection is self‐limiting, and the virus is eliminated within several months. However, in approximately 10% of cases, the infection results in a transformation process being initiated. HR‐HPV DNA is found integrated into the host cell genome in cervical cancers, and, as this process progresses through precancerous lesions to cervical cancer, the frequency of viral genome integration increases.[6](#ijc29872-bib-0006){ref-type="ref"} The E6 and E7 proteins encoded by HPV are among the most well‐known viral oncoproteins and seem to accelerate the progression of cervical cancer by abrogating key inhibitors of cell proliferation.[7](#ijc29872-bib-0007){ref-type="ref"}, [8](#ijc29872-bib-0008){ref-type="ref"} The expression of E6 and E7 is strictly repressed by the virally encoded E2 protein.[9](#ijc29872-bib-0009){ref-type="ref"} Numerous studies have shown that integration of HPV normally involves breaking the viral genome in the E1 and E2 regions, and this results in the inactivation of E1 and E2 due to disruption of their open reading frames.[10](#ijc29872-bib-0010){ref-type="ref"}, [11](#ijc29872-bib-0011){ref-type="ref"}, [12](#ijc29872-bib-0012){ref-type="ref"} The integration‐mediated disruption of the E2 gene and the consequent up‐regulation of E6 and E7 is generally regarded to be a critical step in HPV‐related cervical cancers.

The role(s) of tumor‐related DNA viruses in cancer pathogenesis is mediated through various mechanisms. In spite of the strong oncogenic potency of some proteins encoded by such viruses, integration‐induced aberrant expression or functional change of host genes has also been shown to play a role in virus‐related human malignancies. In line with this, our recent study has demonstrated that the function of integration‐targeted genes (ITGs), which were disrupted directly by HPV integration or the ones closest to the HPV integration site as described before, has a role in determining the oncogenicity of hepatitis B virus (HBV) integration in hepatocellular cancer.[13](#ijc29872-bib-0013){ref-type="ref"} However, in HPV‐related cancers, although HPV DNA integration had been recognized as a major promoting step in malignant transformation, the possible role of ITGs has not received much attention. Several studies have reported the detection of HPV integration into chromosomal sites close to where tumor‐relevant genes mapped[14](#ijc29872-bib-0014){ref-type="ref"}, [15](#ijc29872-bib-0015){ref-type="ref"}; however, an earlier study that reviewed more than 190 integration events did not support the hypothesis that alteration of critical cellular genes can play a major role in HPV‐related cervical carcinogenesis.[16](#ijc29872-bib-0016){ref-type="ref"}

In this study, to systematically understand the pathogenic role(s) that ITGs might have on cervical carcinogenesis, all the available integration data for HR‐HPV types 16 and 18 were collected and reviewed with respect to the characteristics of the loci in the human genome targeted by the integration events. An attempt was also made to interpret the characteristics of the integration sites on human chromosomes and to analyze the distinct functions of ITGs using gene function annotation analysis.

Material and Methods {#ijc29872-sec-0002}
====================

Data collection {#ijc29872-sec-0003}
---------------

To collect all available data, an extensive PubMed search was performed. The key words used were "HPV" and "integration sites." All published articles detailing either HPV breakpoints or chromosomal loci or genes disrupted by HPV integration were included. The full database was then filtered to include only those clinical samples from HPV16 or HPV18 associated cervical cancers, with those originating from other HPV types being excluded. Those integration events obtained from the same sample by the same laboratory were treated in this study as a single event.

Random sites collection {#ijc29872-sec-0004}
-----------------------

The total number of human nucleotide was 3,036,303,846 according to UCSC database, and each nucleotide was represented by a different serial number from 1 to 3,036,303,846. To randomly pick up 200 sites for random control, this serial numbers were imported into SPSS17.0 software (SPSS, Chicago, IL), and came out approximately 6.59 × 10^−8^ (3,036,303,846 encompassed by 200 random sites) various combinations. Then, a random number was selected from the compute filter = (uniform (total number of nucleotide) ≤ 6.59 × 10^−6^), and its corresponding relative nucleotide sites, defined as random nucleotide sites in this manuscript, were extracted for subsequent analysis.

Expressed sequence tag profiles data source {#ijc29872-sec-0005}
-------------------------------------------

Expressed sequence tag (EST) profiles of cervix tissues were downloaded from the UniGene database (<http://www.ncbi.nlm.nih.gov/unigene>/). The EST profiles were inferred from EST counts and the cDNA library sources that showed approximate gene expression patterns. The expression level of each gene was scored as transcripts per million (TPM), that is, the number of transcripts of the gene in every one million clones.

Gene functional annotation analysis {#ijc29872-sec-0006}
-----------------------------------

DAVID (<http://david.abcc.ncifcrf.gov>/) was used to perform the gene functional annotation analysis, and the categories of gene ontology (GO) and KEGG Pathways were chosen as background databases. All genes of *Homo sapiens* obtained from the UCSC database (<http://genome.ucsc.edu>/) were used as the background gene list.

*In vitro* gene functional experiments {#ijc29872-sec-0007}
--------------------------------------

Thirty‐nine cervical cancer tissues and 19 benign lesion tissues were obtained from patients who underwent surgery in Peking University People\'s Hospital and whose diagnosis had been histologically confirmed. HeLa and SiHa cell lines used in this study were tested in the last 2 months by short tandem repeats (STR) matching analysis of their STR profile using the online STR analysis tools provided by the DSMZ database (<http://www.dsmz.de>) for human cell lines.

The sgRNA/Cas9 dual expression vector pSpCas9(BB)‐2A‐GFP was obtained from Addgene (Cambridge, MA). Two specific sgRNA targeted to the HPV genome was designed using the optimized CRISPR design software (<http://crispr.mit.edu>/). The resulting oligonucleotide sequences are listed as follows: sgRNA5170: Top 5′‐CACCGAACTGCAAATGGCCCTACA‐3′; Bottom 5′‐AAACTGTAGGGCCATTTGCAGTTC‐3′. sgRNA36: Top 5′‐CACCGCAGGTGGTGGCAATAAGC‐3′; Bottom 5′‐AAACGCTTATTGCCACCACCTGC‐3′. The primers used for detection of knocked out HPV fragment in HeLa cells were as follows: Primer‐Fwd: 5′‐GTTATTACACAGCTATCAGAGCAA‐3′; Primer‐Rev: 5′‐GGTCTTCTCTGCAATCCATCTGGAGC‐3′. The primers used for detection of wild‐type HPV integration in HeLa cells were primer‐Fwd and sgRNA5170‐Top listed earlier.

HeLa and SiHa cervical cancer cell lines were used for restoring the expression of *MPPED2* using the pLEX‐MCS lentivirus expression system (cat no. OHS4735). The plasmid pLEX‐MCS‐*MPPED2* expressing C‐terminally Myc‐tagged *MPPED2* was constructed by cloning the full‐length coding sequence of *MPPED2* into the eukaryotic expression vector pLEX‐MCS. Cell cycle was measured by flow cytometry, with the percentage of cells in G0/G1, S and G2/M phases calculated using the ModFit programs as previously described.[17](#ijc29872-bib-0017){ref-type="ref"} The EdU incorporation assay was performed using the Cell‐Light EdU DNA cell proliferation kit (RiboBio, Guangzhou, China). Cells (4,000 per well) were grown in 96‐well plates, and at 12 hrs after seeding, they were incubated with 100 μl EdU (50 μM). The remaining steps of the assay were carried out according to the manufacturer\'s instructions, with a fluorescence microscope being used to observe positive cells, which had incorporated EdU. The 3‐(4,5‐dim‐ethylthiazol‐2‐yl)−2,5‐diphenyltetrazolium bromide (MTT) assay method was used for cell proliferation measurements. Cells were seeded at 2,000 cells per well in 96‐well plates, and proliferation was measured every 48 hrs by reading the absorbance at 570 nm using a microplate reader as described previously.[17](#ijc29872-bib-0017){ref-type="ref"}

Statistical analysis {#ijc29872-sec-0008}
--------------------

The *χ* [2](#ijc29872-bib-0002){ref-type="ref"} test and Fisher\'s exact test were used for statistical analyses to compare variables between two groups based on SAS 9.1 for windows (SAS, Cary, NC). All estimates were accompanied by a 95% confidence interval, and *p* \< 0.05 was considered to be statistically significant.

Results {#ijc29872-sec-0009}
=======

Overview of the data collected {#ijc29872-sec-0010}
------------------------------

HPV16 and HPV18 are the two most common HR‐HPV types found in cervical cancers.[2](#ijc29872-bib-0002){ref-type="ref"} After searching the literature, a total of 499 individual integration events with chromosomal locus information were collected from 14 studies, and these were taken into analysis in this study (Supporting Information Tables S1 and S2). They included 379 HPV16 integration events and 120 HPV18 integration events. To investigate the characteristics of HPV integration into the human genome, the integration sites in human chromosomes were analyzed. The methods used collecting the information of HPV integration sites were listed in Supporting Information Table S2. Among the 499 integration events analyzed, 325 events occurred either in the region of a gene or nearby to a gene region. The genes directly disrupted by HPV integration or those whose transcription start sites were closest to the HPV integration sites were categorized as ITGs as previously reported.[13](#ijc29872-bib-0013){ref-type="ref"} A total of 257 ITGs were identified in this study and were used for subsequent analysis. Among these, 38 were named as recurrently targeted host genes (RTGs) because each was targeted by viral integration more than once.

HPV preferentially integrated into intragenic regions and gene‐dense regions of the human genome {#ijc29872-sec-0011}
------------------------------------------------------------------------------------------------

Given that both HBV and human immunodeficiency virus have been shown to preferentially integrate into the transcription active regions, including intragenic regions and gene‐dense regions of human chromosomes,[13](#ijc29872-bib-0013){ref-type="ref"}, [18](#ijc29872-bib-0018){ref-type="ref"} it was reasonable to assume that HPV integration might also exhibit such a preference. To clarify if this assumption was correct, 116 integration sites obtained by next generation sequencing derived from two studies (Refs. 5 and 13) with exact positional relationship to a gene were analyzed (Supporting Information Table S1). To avoid any bias, those integration sites identified by other methods were excluded. First, whether the distribution pattern of integration sites was enriched in intragenic regions in human genome was analyzed. As shown in Figure [1](#ijc29872-fig-0001){ref-type="fig"} *a*, some 50% of the integration sites were located in intragenic regions (including exon and intron regions), which was significantly higher than expected, based on the proportion of the human genome encompassed by such region[13](#ijc29872-bib-0013){ref-type="ref"} (50% observed in the integration group *vs*. 39% expected if integration was random; *p* \< 0.01; Fig. [1](#ijc29872-fig-0001){ref-type="fig"} *a*). More detailed analysis of the 116 integration sites revealed that there was a statistically significant preferential localization in exons (12.1% detected in the integration group *vs*. 2.3% expected if integration was random; *p* \< 0.001; Fig. [1](#ijc29872-fig-0001){ref-type="fig"} *a*). By contrast, there was no preferential localization of integration events in introns (37.9% detected in the integration group *vs*. 36.7% expected for random integration; Fig. [1](#ijc29872-fig-0001){ref-type="fig"} *a*). It was believed that transcriptional active region of chromatins were more accessible for HPV integration. Next, to analyze whether HPV integrates preferentially into the chromatin configuration where genes enriched and were transcriptionally active, the number of genes in a 100 kb region upstream and/or downstream of the 116 precisely localized integration sites were statistically analyzed against 200 sites randomly picked across the whole human genome. A total of 303 genes surrounding the 116 integration sites were catalogued; this is significantly more than the 309 genes identified as surrounding the 200 control sites (*p* \< 0.001; Fig. [1](#ijc29872-fig-0001){ref-type="fig"} *b*). To validate the hypothesis further, the transcription status of host genes surrounding the integration sites were analyzed. For this analysis, TPM values obtained from normal cervix tissue were used to evaluate the transcriptional activity of host cellular genes. Using TPM values from EST profiles, the expression status of the genes surrounding the HPV integration sites were compared with those of the genes surrounding the randomly selected control sites. The expression level of the 79 genes that mapped within 15 kb upstream or downstream of the 116 HPV integration sites were marginally higher than that of the 94 genes located at a similar distance from the 200 randomly selected control sites (*p* = 0.081; Fig. [1](#ijc29872-fig-0001){ref-type="fig"} *c*).

![Distribution of HPV integration sites in the human genome. (*a*) The percentage of genes located in intragenic, exon and intron regions. (*b*) Number of genes located within 100 kb up‐ and downstream of integration sites. Data are presented in boxes and whiskers' style, which represents the medians and ranges of the data. (*c*) The transcriptional activities of host genes surrounding HPV integration sites. "TPM" indicates the expression level of those genes in normal cervix tissues. \*\**p* \< 0.01; \*\*\**p* \< 0.001.](IJC-138-1163-g001){#ijc29872-fig-0001}

HPV DNA preferentially integrated into some hotspots in human chromosomes {#ijc29872-sec-0012}
-------------------------------------------------------------------------

The results aforementioned demonstrated that HPV preferentially integrates into transcriptionally active regions. It has been suggested that there were hotspots for HPV integration in specific human chromosomes.[11](#ijc29872-bib-0011){ref-type="ref"}, [16](#ijc29872-bib-0016){ref-type="ref"} To provide further evidences and also to identify whether there were any previously unrevealed hotspots, the distribution characteristics of the integration sites across the human genome were investigated based on this relatively large study cohort. In this study, all integration sites were normalized to standard "chromosome bands." For example, they were normalized to "8q24" irrespective of whether the integration location was "8q24.1" or "8q24.2." To reduce the bias caused by length difference between different chromosome bands, the "chromosome band" was represented by ratio based on the proportion of the human genome encompassed by each chromosome band. The integration sites included in the dataset were assigned to all 23 human chromosomes (Supporting Information Fig. S1), with some regions being targeted more frequently by HPV16/18 integration than expected (Fig. [2](#ijc29872-fig-0002){ref-type="fig"} *a*). Among these hotspots, there were 34 integration events localized to 8q24, making it the most frequently affected chromosome band, followed by 17q23 (14 events), 13q22 (12 events), 1p36 and 3q28 (11 events each). When the hotspot distribution of HPV16 and HPV18 integration sites were analyzed separately, the overall hotspot distribution remained (Figs. [2](#ijc29872-fig-0002){ref-type="fig"} *b* and [2](#ijc29872-fig-0002){ref-type="fig"} *c*). However, there were some differences between the two viruses; thus, 1p36 was only disrupted by HPV16 (integrated by HPV16 *vs*. integrated by HPV18; *p* = 0.07), whereas the HPV18 genome integrated more frequently into 8q24 (integrated by HPV16 *vs*. integrated by HPV18; *p* = 0.0006) and 17q23 (integrated by HPV16 *vs*. integrated by HPV18; *p* = 0.1; Fig. [2](#ijc29872-fig-0002){ref-type="fig"} *d*).

![The hotspots of HPV integration into human chromosomes. Comparison of observed chromosome break points in the human genome with expected. Chromosome break points integrated by (*a*) HPV16/18, (*b*) HPV16 and (*c*) HPV18, compared with expected, respectively. (*d*) Different distribution of chromosome break points in different HPV types. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](IJC-138-1163-g002){#ijc29872-fig-0002}

Most of the ITGs in chromosome hotspots and the RTGs were functionally cancer related {#ijc29872-sec-0013}
-------------------------------------------------------------------------------------

A total of 80 ITGs were mapped to the hotspots as described earlier. It would be interesting to investigate whether these ITGs were functionally cancer‐related genes. Here, the term "cancer‐related gene" was defined in the National Center for Biotechnology Information (NCBI) database as oncogene or tumor suppressor gene, or that has been reported to be involved in carcinogenesis. As expected, 61 of the 80 ITGs analyzed were tumor‐related genes (Table [1](#ijc29872-tbl-0001){ref-type="table-wrap"}), which implicated that HPV DNA fragment integrated preferentially into genomic hotspots where tumor‐related genes located. Presumably, the cells in which such integration events occurred acquired survival and proliferation advantages during cervical carcinogenesis.

###### 

ITGs in hotspots and relationship with tumors

          Integrated times   ITGs in the hotspot and relationship with tumors                                                                               
  ------- ------------------ -------------------------------------------------- ---- ---------------------------------------------------------------------- --------------------------
  1p36    11                 11                                                 0    ***CASZ1, C1orf201, WASF2, ALPQTL2***                                  *C1orf196*
  1q21    6                  6                                                  0    ***[RPS27]{.ul}, USP21, GOLPH3L***                                     *LOC645166*
  2q22    8                  5                                                  3    ***[LRP1B]{.ul}, [PABPC1P2]{.ul}***                                    *LOC151128*
  2q33    6                  6                                                  0    ***[ORC2]{.ul}, PARD3B, RTN4IP1***                                     
  3q26    9                  9                                                  0    ***[MECOM]{.ul}, MDS1, ATP11B, SOX2***                                 *TNIK*
  3q28    11                 9                                                  2    ***[TP63]{.ul}, [LEPREL1]{.ul}, FAM79B, CLDN16, CLDN1***               
  6q21    6                  6                                                  0                                                                           *FIG4*
  8p11    7                  4                                                  3                                                                           *ZNF703*
  8q24    34                 17                                                 17   ***[POU5F1B]{.ul}, [MYC]{.ul}, [AGO2]{.ul}, GPAA1, RASSF6, DEPTOR***   *[LOC727677]{.ul}*
  9q22    8                  5                                                  3    ***[FANCC]{.ul}***                                                     *[C9orf3]{.ul}*
  9q34    8                  5                                                  3    ***Notch1, EGFL7***                                                    *SLC25A25*
  13q21   8                  8                                                  0    ***DACH1***                                                            
  13q22   12                 10                                                 2    ***[KLF5]{.ul}, KLF12***                                               
  14q24   9                  6                                                  3    ***RNGTT, RAD51B, GLI2***                                              
  14q32   6                  6                                                  0    ***[BCL11B]{.ul}, TNFAIP2, SLC24A4***                                  
  17q12   7                  7                                                  0    ***MED24, PLXDC1, IKZF3, GRB7, HNF1B***                                *C‐CR7*
  17q21   7                  5                                                  2    ***[ERBB2]{.ul}, BRCA1, STARD3, EIF1, RARA***                          *KRT40*
  17q23   14                 8                                                  6    ***[TMEM49]{.ul}, [CGI‐147]{.ul}***                                    *TUBD1*
  19p13   8                  7                                                  1    ***PRKACA, NANOS3, ARID3A, HMHA1***                                    *MOB3A, ZNF506, GATAD2A*
  19q13   6                  4                                                  2    ***CEACAM5***                                                          *LOC126235, Q8N6Q3*
  20p12   7                  6                                                  1    ***[MACROD2]{.ul}, FLRT3***                                            
  Xp22    6                  6                                                  0    ***STS, NHS, PDK3***                                                   *FAM48B2, VCX2*

The bold genes have been reported to be tumor‐related based on NCBI database, whereas the underlined genes were recurrently integration‐targeted genes.

Abbreviations: Y: Yes; means that these genes had been reported to be a tumor‐related gene; N: no; means that there was no report about the relationship between this gene and tumors.

In addition to these 80 ITGs, 38 RTGs recurrently targeted by HPV integration were also reviewed. *MYC* came out to be the gene most frequently affected by viral integration (13 events), followed by trans‐membrane protein 49 (*TMEM49*; five events) and *FANCC* and *KLF5* (four events). A further 12 genes were affected three times, leaving 22 of the RTGs affected twice in the dataset analyzed. Consistent with the observation that genes in chromosome hotspots were tumor related, 29 of the 38 RTGs have also been reported to be tumor related (Table [2](#ijc29872-tbl-0002){ref-type="table-wrap"}).

###### 

Recurrent targeted genes and relationship with tumors

  Gene symbol         Integrated times   Cancer related   Gene function                                                                                                                                                            Reference (PMID)
  ------------------- ------------------ ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------
  *MYC*               13                 Y                Negative regulation of apoptotic process; positive regulation of cell proliferation                                                                                      NCBI gene
  *TMEM49* (*VMP1*)   5                  Y                *VMP1* is involved in multiple cancers as a tumor suppressor gene through regulating autophagy, inhibiting metastasis and proliferation of hepatocellular carcinoma      24549370; 24365149; 22971212
  *FANCC*             4                  Y                DNA repair                                                                                                                                                               23028338; 17490643
  *KLF5*              4                  Y                Acts as an oncogene in kinds of tumors through positive regulation proliferation                                                                                         24626089; 23913682
  *C9orf3*            3                  N                                                                                                                                                                                         
  *BCL11B*            3                  Y                *BCL11B* tumor suppressor inhibits *HDM2* expression in a p53‐dependent manner; mutation and decreased expression of this gene is related with multiple cancers          22450536; 22245141; 21878675
  *COX4I2*            3                  Y                                                                                                                                                                                         22320183
  *GLS*               3                  Y                Promotes glioma cell lines proliferation                                                                                                                                 24276018
  *HTERT*             3                  Y                Telomerase reverse trancriotitase                                                                                                                                        NCBI gene
  *LOC727677*         3                  N                                                                                                                                                                                         
  *LRP1B*             3                  Y                Inhibits cell migration                                                                                                                                                  12004004; 23521319
  *NR4A2*             3                  Y                *NR4A2* emerges as an important nuclear factor linking gastrointestinal inflammation and cancer                                                                          23821160; 23322982
  *TP63*              3                  Y                Keratinocyte proliferation; negative regulation of apoptotic process                                                                                                     NCBI gene
  *RAP2B*             3                  Y                Belongs to a family of *RAS*‐related genes; over expressed in tumors                                                                                                     17316888; 16204058
  *RPS27*             3                  Y                Regulates apoptosis                                                                                                                                                      17057733; 2117008.
  *PABPC1P2*          3                  N                                                                                                                                                                                         
  *ERBB2*             2                  Y                Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors                                              NCBI gene
  *CEACAM5*           2                  Y                Negative regulation of apoptotic process                                                                                                                                 NCBI gene
  *FHIT*              2                  Y                Aberrant transcripts from this gene were found in about half of all esophageal, stomach and colon carcinomas through apoptotic signaling pathway by p53 class mediator   24556720; 24370550
  *AFP*               2                  Y                Marker of liver tumor                                                                                                                                                    24425104
  *CHS1*              2                  N                                                                                                                                                                                         
  *DRAP1*             2                  N                                                                                                                                                                                         
  *IL8*               2                  Y                Negative regulation of cell proliferation; cell cycle arrest                                                                                                             NCBI gene
  *KLF12*             2                  Y                Enhances tumor cell invasive potential                                                                                                                                   19588488
  *KLHL3*             2                  N                                                                                                                                                                                         
  *LEPREL1*           2                  Y                It can be hypermethylated and acts as a tumor suppressor in breast cancer                                                                                                19436308
  *LIPC*              2                  Y                                                                                                                                                                                         23343765
  *MACROD2*           2                  Y                Deletion of this gene is found in cancer genomes                                                                                                                         23805207
  *MECOM*             2                  Y                Positive regulation of proliferation                                                                                                                                     22372463
  *SLC25A36*          2                  N                                                                                                                                                                                         
  *ORC2*              2                  Y                Overexpressed in kinds of tumors; G1/S transition of mitotic cell cycle                                                                                                  16163736; NCBI gene
  *FER1L3*            2                  N                                                                                                                                                                                         
  *POU5F1P1*          2                  Y                Overexpressed in kinds of tumors and was correlated with metastasis                                                                                                      20017164; 21748294
  *RAD51B*            2                  Y                Overexpression of this gene was found to cause cell cycle G1 delay and cell apoptosis                                                                                    NCBI gene
  *DRAP1*             2                  N                                                                                                                                                                                         
  *RPS27*             2                  Y                Enhances the DNA repair capacity; promote apoptosis through p53 signaling pathway                                                                                        23826192; 17057733
  *SH3PXD2A*          2                  Y                Promotes prostate cancer metastasis and invasion in multiple cancer types                                                                                                24174371; 23873940
  *AGO2*              2                  Y                Promotes angiogenesis, metastasis                                                                                                                                        24886719; 24427355

Abbreviations: Y: Yes; means that these genes had been reported to be a tumor‐related gene. N: no; means that there was no report about the relationship between this gene and tumor.

Genes affected by HPV integration were distinctly clustered in tumor‐related terms {#ijc29872-sec-0014}
----------------------------------------------------------------------------------

To gain further insights into the possible roles that the ITGs may play in HPV‐related cervical cancer, they were all subjected to functional annotation analysis using DAVID software. In total, 226 of the 257 ITGs could be identified in DAVID analysis. GO analysis revealed that the genes identified were significantly enriched in the following nine terms: "angiogenesis," "positive regulation of transcription," "cell morphogenesis involved in differentiation," "negative regulation of gene expression," "cell migration," "muscle tissue development," "regulation of cell proliferation," "cell adhesion" and "regulation of apoptosis and cell death" (*p* \< 0.05; Fig. [3](#ijc29872-fig-0003){ref-type="fig"} *a*). Further, KEGG pathway annotation analysis showed that three pathways were significantly clustered: the "ErbB signaling pathway," the "mTOR signaling pathway" and the "Pathways in cancer" (*p* \< 0.05; Fig. [3](#ijc29872-fig-0003){ref-type="fig"} *a*), all of which are tumor‐related pathways. The term "Bladder cancer" was also marginally enriched (*p* = 0.075; data not shown). To analyze whether there was any difference between HPV16 and HPV18, GO and KEGG analysis was performed on these two groups separately. The ITGs involving integration of HPV18 were enriched in "insulin signaling pathway" terms, whereas HPV16/18 or HPV16 integrations did not show this association (Figs. [3](#ijc29872-fig-0003){ref-type="fig"} *b* and [3](#ijc29872-fig-0003){ref-type="fig"} *c*). The RTGs were also subjected to GO and KEGG analysis, significant enrichment in "regulation gene expression," "regulation of cell proliferation" and "regulation of apoptosis and cell death," as well as the term of "pathways in cancer" were identified (*p* \< 0.05; Fig. [3](#ijc29872-fig-0003){ref-type="fig"} *d*).

![Functional annotation analysis of ITGs. Comparison of gene oncology and KEGG pathway analysis between observed genes integrated by (*a*) HPV16/18, (*b*) HPV16, (*c*) HPV18 and (*d*) recurrent targeted by HPV16/18 integration and expected, respectively. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](IJC-138-1163-g003){#ijc29872-fig-0003}

According to their precise integration site on the chromosome, the ITGs were further grouped into those in which the insertion of viral DNA resulted in *d*isruption of the cellular gene (dITGs) with the viral DNA being inserted directly into the intragenic region of the gene, and those in which integration occurred *c*lose to but not actually within the cellular gene (cITGs). GO and KEGG analysis was performed on these groups separately. This revealed that dITGs were enriched in the following terms: "low‐density lipoprotein binding," "transcription factor activity," "intracellular signaling cascade" and "keratinocyte proliferation" (*p* \< 0.05; Supporting Information Table S3), whereas cITGs were enriched in: "transcription factor activity," "blood vessel morphogenesis" and "Wnt signaling pathway" (*p* \< 0.05). In addition, the cITGs also showed enrichment in the terms "negative regulation of apoptosis" (*p* = 0.058), "epidermis morphogenesis" (*p* = 0.061) and "positive regulation proliferation" (*p* = 0.084) to some extent (Supporting Information Table S3). As expected, PubMed search indicated that tumor suppressors, such as *TP63* and *CDH13*, which negatively regulate keratinocyte proliferation, were linked to the gene structure destroyed dITGs group. Whereas, the cITGs contained known oncogenes such as *BCL11B, NR4A2, MYC* and *ARHGDIA* that could negatively regulate apoptosis.

"Knocking out" of the integrated HPV fragment decreased the expression of *MYC* in HeLa cells {#ijc29872-sec-0015}
---------------------------------------------------------------------------------------------

It has been suggested that in the HeLa cell line, the over expression of *MYC* was modulated by the integrated HPV genome ∼500 kb upstream of it, *via* a mechanism involving long distance chromatin interaction.[19](#ijc29872-bib-0019){ref-type="ref"} To confirm whether removal of the integrated HPV fragment had any effect on *MYC*, the CRISPR/Cas9 system was used to remove the integrated HPV DNA fragment. Then, the subsequent change in *MYC* expression was detected by real‐time reverse transcription polymerase chain reaction (RT‐PCR). Figure [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐i shows the construction strategy used, with two sgRNAs targeted to the integrated HPV fragment. To confirm that the dual sgRNA could mediate cleavage of the integrated HPV fragment in HeLa cells, PCR was performed using different primer sets (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐i), and the products were detected by agarose gel electrophoresis. First, the specific cleavage of the integrated HPV DNA was analyzed. Forty‐eight hours after transfection of the HeLa cells with the sgRNA/Cas9 dual expression vectors, cellular DNA was extracted and PCR was performed using Primer‐Fwd and Primer‐Rev (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐i). As expected, a ∼750 bp length PCR amplicon was detected (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐ii, shown as "KO"), indicating that the dual sgRNAs had promoted the removal of the 5,134 bp integrated HPV fragment from the HeLa cell genome. Next, the PCR product was sequenced, to confirm that the dual sgRNAs had precisely guided site‐specific cleavage by the CRISPR/Cas9 system (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐i). To obtain information on cleavage efficiency, primers located in the viral and host genome were designed, which guaranteed the specific amplification of the viral--host junction sequence (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐i). As expected, PCR assay revealed a marked decrease of the viral--host junction fragment in sgRNA‐transfected cells as compared with its control vector‐transfected counterpart (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐ii, shown as "CTRL"). Consistently, a cleavage efficacy of approximately 70% was confirmed by real‐time PCR (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐iii). Subsequently, the change of *MYC* expression brought about by the CRISPR/Cas9‐mediated removal of the integrated HPV fragment was evaluated by real‐time RT‐PCR, and the expression of *MYC* was decreased by approximately 30% in the sgRNA‐transfected cells (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *a*‐iv).

![The cancer relativity of HPV ITGs. (*a*‐i) Construction strategy of dual sgRNAs used for "knocking out" the integrated HPV fragment in HeLa cells with CRISPR/Cas9. A 5,134 bp integrated HPV fragment was expected to be "knocked out" by the dual sgRNAs. If this integrated HPV fragment was successfully removed by sgRNA cleavage, a ∼750 bp PCR product would be detected using Primer‐Fwd and Primer‐Rev. The region covering the viral--host junction sequence shown between the red arrows amplified was used for detecting cleavage efficiency. For amplification of this region, primers (Primer‐Fwd and sgRNA5170‐Top) were set in the host and virus genome, respectively, and the PCR amplicon expected was ∼200 bp. (*a*‐ii) "Knock‐out" of the integrated HPV fragment was confirmed by PCR assay in HeLa cells transfected with sgRNA or vector plasmids. The expected ∼750 bp PCR amplicon, labeled sgRNA‐KO, was detected using Primer‐Fwd and Primer‐Rev, indicating the successful knock out of the integrated HPV fragment. Direct sequencing of the junction region of the ∼750 bp amplicon is shown in (*a*‐i). The ∼200 bp PCR amplicon covering the viral--host junction sequence was amplified using Primer‐Fwd and sgRNA5170‐Top and used as control. (*a*‐iii) Cleavage efficiency was evaluated by real‐time PCR using the same primer pair covering the viral--host junction. (*a*‐iv) Expression of *MYC* was detected by real‐time RT‐PCR in HPV knocked out HeLa cells and nontransfected controls. (*b*) Expression of *THSD4*, *FANCC*, *LEPREL1*, *MPPED2*, *TMEM49* and *SLC256A36* in normal cervix tissues, cervical cancer tissues and HeLa, SiHa and CaSki cell lines was detected by real‐time PCR. (*c*‐i, *d*‐i) The proportion of cells at different stages of the cell cycle was detected by flow cytometry in HeLa and SiHa cells with ectopic expression of *MPPED2*. (*c*‐ii, *d*‐ii) The effect of *MPPED2* on cell proliferation was evaluated using EdU incorporation assays in HeLa and SiHa cell lines. (*c*‐iii, *d*‐iii) Quantitative analysis of EdU incorporation assays. (*c*‐iv, *d*‐iv) The ability of cell growth in HeLa and SiHa cell lines with ectopic expression of *MPPED2* was measured by MTT assays. \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](IJC-138-1163-g004){#ijc29872-fig-0004}

*MPPED2* may act as a tumor suppressor gene in cervical cancer {#ijc29872-sec-0016}
--------------------------------------------------------------

To investigate whether there were novel candidate cervical cancer‐related genes from those ITGs identified in this study, the expression of the six ITGs (*THSD4*, *FANCC*, *LEPREL1*, *MPPED2*, *TMEM49*, and *SLC256A36*) was detected and compared by real‐time PCR in normal cervix tissue, cervical cancer tissues and cell lines. Of them, *LEPREL1*, *TMEM49*, *SLC25A36* and *FANCC* were repeatedly targeted by HPV integration, and so we speculated that these genes may have much more chance to play roles in cervical cancer. Because most of the ITGs were affected by HPV integration only for once, the role of these genes in cervical cancers should also attract our attention. To choose candidate genes from them, microarray‐based expression profiles data were used to preliminary evaluate the aberrant expression of those ITGs[20](#ijc29872-bib-0020){ref-type="ref"}; *MPPED2* and *THSD4* were two genes, which were abnormally expressed and have never been reported in cervical cancer. Of them, *THSD4, LEPREL1* and *MPPED2* were significantly decreased in tumor tissues and cell lines compared with that in normal tissues (Fig. [4](#ijc29872-fig-0004){ref-type="fig"} *b*). Among the aberrant expressing genes, *MPPED2* showed the greatest down‐regulation in cervical cancers as well as in cell lines compared with its expression level in normal tissue. *MPPED2* has also been suggested as a tumor suppressor in neuroblastoma, because it caused both tumor cell apoptosis and cell cycle retardation *in vitro*.[21](#ijc29872-bib-0021){ref-type="ref"} However, the biological role of *MPPED2* as a tumor suppressor in cervical cancer has remained elusive. Therefore, its function was studied *in vitro* using two cervical cell lines (HeLa and SiHa). Analysis of the cell cycle progression by flow cytometry showed that ectopic expression of *MPPED2* in either of these cell lines caused a significant block in the G1/S phase transition. As shown in Figures [4](#ijc29872-fig-0004){ref-type="fig"} *c*‐i and [4](#ijc29872-fig-0004){ref-type="fig"} *d*‐i, cell populations were increased in G1 phase and decreased in S phase, compared with control cells. The cell growth retardation was further confirmed using an EdU incorporation assay, which showed that ectopic *MPPED2* expressing cells incorporated less EdU when compared with control cells (Figs. [4](#ijc29872-fig-0004){ref-type="fig"} *c*‐ii--iii and 4*d*‐ii--iii). Consistent with these data, an MTT assay revealed that restoration of *MPPED2* expression suppressed cell proliferation (Figs. [4](#ijc29872-fig-0004){ref-type="fig"} *c*‐iv and [4](#ijc29872-fig-0004){ref-type="fig"} *d*‐iv). Taken together, these results implicated *MPPED2* as a possible tumor suppressor in cervical cancer. The cause of *MPPED2* down‐regulation in cervical cancer needs further study. It is worthwhile to emphasize that the role of HPV integration should not be over interpret.

Discussion {#ijc29872-sec-0017}
==========

Following the initial discovery of HPV DNA in the human genome, various studies have demonstrated its role in cervical carcinogenesis. In recent years, viral genome DNA integration‐induced aberrant expression or functional change of host cellular genes has also been suggested as playing a role in a number of virus‐related human malignancies.[13](#ijc29872-bib-0013){ref-type="ref"}, [18](#ijc29872-bib-0018){ref-type="ref"} To provide evidence that the same mechanism was also involved in HPV‐related cervical cancer, the pattern of HPV integration into the human genome was analyzed. The large‐scale analysis undertaken in this study involved 499 integration events and allowed the conclusion that HPV DNAs prefer to integrate into intragenic and gene‐dense regions similar to what has been observed in HBV^13^ and human immunodeficiency virus integration.[18](#ijc29872-bib-0018){ref-type="ref"} Importantly, viral integration into such regions increases the potential influence that the HPV integration events may have on host cellular genes. Besides, we searched the NCBI database and found that the insights that frequency of intragenic integration and integration into transcriptionally active chromosomal regions were firstly put forward. For the HPV integration hotspots, through the comprehensive analysis, we confirmed current hotspots such as 2q22, 2q33, 3q28, 8q24 9q34, 13q21‐22 and 17q21 reported by previous articles and found out some new hotspots such as 1p36, 3q26, 9q22, 17q12 and 20p12.

Analysis of the chromosomal hotspot ITGs in this cohort revealed that the majority of cellular genes identified were tumor related. Supporting Information Figure S2 illustrates in detail the physical map of the genes affected by HPV integration at several of the chromosomal hotspots. Among those identified, *MYC* and *TMEM49* are illustrative. The cellular oncogene *MYC*, located in the chromosomal hotspot 8q24, was the gene most recurrently targeted by viral integration. Moreover, a recent study has strongly suggested that through mechanism called long distance chromatin interaction, the HPV18 genome integrated ∼500 kb upstream of *MYC* markedly activated its transcription, which resulted in the robust growth characteristics of the HeLa cell line.[19](#ijc29872-bib-0019){ref-type="ref"} Consistent with this, as shown in this study, CRISPR/Cas9‐mediated "knock out" of the integrated HPV fragments resulted in significantly decreased expression of *MYC*. This result indicates that integration of HPV in human genome indeed exhibited influence on ITGs expression. *TMEM49* is located in the second commonest HPV integration site 17q23.1. This gene encodes a protein that is located in the plasma membrane and plays an important role in cell--cell connections and tight junction formation. It has been reported to act as a tumor suppressor in a variety of tumors, including breast,[22](#ijc29872-bib-0022){ref-type="ref"} pancreas cancer,[23](#ijc29872-bib-0023){ref-type="ref"} as well as in hepatocellular cancer.[24](#ijc29872-bib-0024){ref-type="ref"} Because all five integration events categorized in this cohort were located in the intragenic region of *TMEM49*, it will be interesting to detect in the future whether this gene were commonly mutant in cervical cancers.

The analysis of the RTGs identified in this large‐scale review study also supports our hypothesis. The fact that the majority of RTGs seem to be functionally cancer related strongly suggests that integration‐induced dysregulation of host cellular genes involved in cervical carcinogenesis represents a common oncogenic mechanism of HPV integration. The characteristics of the RTGs prompted the functional annotation of all the ITGs. As expected, functional annotation revealed that most of the ITGs were enriched in tumor‐related terms and pathways, including GO terms of "regulation of proliferation" and "regulation of apoptosis" and the KEGG terms of "ErbB signaling pathway," "mTOR signaling pathway" and "pathway in cancer" term. In consistent with our results in the current study, a recent report also showed that ITGs were enriched in tumor‐related KEGG terms.[25](#ijc29872-bib-0025){ref-type="ref"}

The analysis undertaken in this study strongly indicates that dysregulation of ITGs contributes to cervical carcinogenesis. Four patterns of how this occurs can be put forward. First, in the case of tumor suppressor genes such as *TMEM49* and *CASZ1* (castor zinc finger 1),[15](#ijc29872-bib-0015){ref-type="ref"} irrespective of whether the integration event occurred in introns or exons, a decrease in expression and/or a loss of function of the genes would occur (Supporting Information Figs. S2*a* and S2*b*). Second, integration events that result in the formation of viral--cellular fusion transcripts could be expected to promote oncogenicity. Third, in the case of oncogenes, the majority of integration events were located within promoter or upstream regions, and this would be expected to trigger the transcriptional activation of the gene (Supporting Information Fig. S2*d*). Finally, vicinal amplification or deletion close to integration sites may also lead to de‐regulation the host genes. The first two were termed as dITGs, whereas the last two, to some extent, could be termed as cITGs in this study. Perfectively in concordance, different enriched terms of dITGs and cITGs were revealed by GO and KEGG analysis, with dITGs enriched in tumor suppressor related terms, whereas cITGs mostly enriched in oncogene‐related terms. In addition, functional restoration experiments in this study implicated that *MPPED2*, one of the ITGs, acted as a potential new tumor suppressor in cervical cancer.

In conclusion, through a systematic comprehensive review and experimental investigation, this study has revealed that the viral integrations were prone to occur into transcriptionally active regions of the cellular genome. The integration‐targeted host cellular genes were found to be enriched in tumor‐related terms, indicating that alteration of human genome and functional aberration of ITGs by HPV integration might be a second mechanism that is relevant to HPV\'s contribution to cervical oncogenesis.
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